TransMedics Group, Inc. $TMDX Shares Bought by Odyssean LLC

Odyssean LLC grew its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 191.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,814 shares of the company’s stock after purchasing an additional 8,424 shares during the period. Odyssean LLC’s holdings in TransMedics Group were worth $851,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in TMDX. Goldman Sachs Group Inc. raised its holdings in shares of TransMedics Group by 50.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock worth $117,506,000 after purchasing an additional 322,353 shares in the last quarter. Two Sigma Investments LP boosted its holdings in TransMedics Group by 54.2% during the third quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock worth $71,291,000 after buying an additional 223,409 shares in the last quarter. Wellington Management Group LLP boosted its holdings in TransMedics Group by 100.5% during the fourth quarter. Wellington Management Group LLP now owns 433,321 shares of the company’s stock worth $52,713,000 after buying an additional 217,180 shares in the last quarter. Deutsche Bank AG acquired a new position in TransMedics Group in the second quarter worth approximately $14,415,000. Finally, Bank of New York Mellon Corp acquired a new position in TransMedics Group in the second quarter worth approximately $12,869,000. Institutional investors own 99.67% of the company’s stock.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the sale, the director directly owned 16,642 shares of the company’s stock, valued at $1,249,148.52. The trade was a 36.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by company insiders.

TransMedics Group Stock Performance

TransMedics Group stock opened at $92.22 on Thursday. TransMedics Group, Inc. has a fifty-two week low of $60.10 and a fifty-two week high of $156.00. The firm’s 50 day simple moving average is $78.59 and its 200-day simple moving average is $94.23. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07. The company has a market cap of $3.19 billion, a P/E ratio of 23.71 and a beta of 1.90.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The firm had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. During the same quarter last year, the company posted $0.92 EPS. The firm’s revenue was up 20.7% compared to the same quarter last year. As a group, equities research analysts predict that TransMedics Group, Inc. will post 1.46 EPS for the current year.

Analysts Set New Price Targets

TMDX has been the topic of several research reports. Zacks Research cut TransMedics Group from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Stifel Nicolaus lifted their target price on TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, June 18th. Weiss Ratings lowered TransMedics Group from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, July 28th. Piper Sandler reaffirmed an “overweight” rating and set a $100.00 target price (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. Finally, TD Cowen reiterated a “buy” rating and issued a $120.00 price target on shares of TransMedics Group in a research report on Wednesday, July 1st. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $124.18.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.